Conor Takes Stent Defense Down Under With Patent Invalidation Suit
This article was originally published in The Gray Sheet
Executive Summary
Conor MedSystems' proactive efforts to protect its CoStar paclitaxel-eluting stent have expanded to Australia
You may also be interested in...
Courts In Netherlands And UK Differ In Conor/Angiotech Patent Dispute
Conor Medsystems and Boston Scientific are both claiming small victories in their ongoing patent dispute related to paclitaxel-eluting stent technology after a Dutch court ruled in favor of Boston Scientific during the same week that a United Kingdom court sided with Conor
Courts In Netherlands And UK Differ In Conor/Angiotech Patent Dispute
Conor Medsystems and Boston Scientific are both claiming small victories in their ongoing patent dispute related to paclitaxel-eluting stent technology after a Dutch court ruled in favor of Boston Scientific during the same week that a United Kingdom court sided with Conor
Conor Set To Enroll Pivotal U.S. Study For CoStar, Talks Up DES Pipeline
Conor Medsystems expects to begin enrolling a 1,700-patient, U.S. pivotal trial for itsCoStar paclitaxel-eluting, cobalt-chromium coronary stent in the next few weeks